Eli Lilly (NY:LLY)

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

Topics Artificial Intelligence Economy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Topics Economy Intellectual Property

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Alphabet Inc. (GOOGL) Deep Dive: Navigating the Agentic Era and the $180 Billion AI Bet

February 26, 2026

As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain...

Via Finterra

Topics Artificial Intelligence Initial Public Offering Workforce

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗

February 26, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know.

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 25, 2026

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

Topics Artificial Intelligence

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

Topics Stocks

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

Topics Intellectual Property

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Labor Resilience Defies 'Soft Landing' Narrative: ADP Pulse Data Shows Four Weeks of Growth, Forcing Fed Rethink

February 25, 2026

The U.S. labor market is flashing a surprising signal of late-cycle strength as the shortest month of the year comes to a close. Despite a lukewarm monthly headline in early February, the latest ADP...

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

Topics Artificial Intelligence Economy Stocks

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗

February 25, 2026

Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset.

Topics Economy

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗

February 25, 2026

Via Benzinga

Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect

February 25, 2026

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

Topics Artificial Intelligence

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

It would be a near-miracle gain.

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗

February 25, 2026

Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect.

Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

February 24, 2026

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect.

Topics World Trade

Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect

February 24, 2026

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Topics World Trade

Why Eli Lilly Stock Slumped Today ↗

February 24, 2026

Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.

Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA ↗

February 24, 2026

A Tale of Two Titans: Eli Lilly Surges as Novo Nordisk Stumbles in the Weight Loss Price War

February 24, 2026

The global pharmaceutical landscape underwent a seismic shift today, February 24, 2026, as the two pioneers of the weight loss drug revolution reported vastly different outlooks for the coming year....

Meta is the only "Magnificent Seven" stock that has not had a stock split.

Stock-Split Watch: Is Meta Platforms Next? ↗

February 24, 2026

TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair

February 24, 2026

Via Investor Brand Network

Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation

February 24, 2026

As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4...

Via Finterra

Topics Earnings Economy Initial Public Offering

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

February 24, 2026

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release...

Via FinancialNewsMedia

Is Johnson & Johnson Stock Outperforming the Nasdaq?

February 24, 2026

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks World Trade

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗

February 24, 2026

According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.

Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was...

Topics Artificial Intelligence

Elanco (NYSE:ELAN) Surprises With Q4 CY2025 Sales

February 24, 2026

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.